Estimates of vaccine effectiveness of the updated monovalent XBB ...

The short-term effectiveness of the XBB.1.5 vaccine against symptomatic COVID-19 infection, hospitalization, and receipt of oxygen therapy ...

Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) - CDC

Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable ...

Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID ...

Using a test-negative, case-control design, we estimated effectiveness of an updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccine dose against sequence- ...

Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5 ...

However, few estimates of updated vaccine effectiveness (VE) against medically attended illness are available. ... VE against COVID-19–associated ...

Estimates of vaccine effectiveness of the updated monovalent XBB ...

Estimates of vaccine effectiveness of the updated monovalent XBB.1.5. COVID-19 vaccine against symptomatic SARS-CoV-2 infection, hospitalization, and receipt ...

Estimates of Vaccine Effectiveness of the Updated Monovalent XBB ...

The short-term effectiveness of the XBB.1.5 vaccine against symptomatic COVID-19 infection, hospitalization, and receipt of oxygen therapy in South Korea was ...

Estimated Effectiveness of the BNT162b2 XBB Vaccine Against ...

Among those who received the BNT162b2 XBB vaccine, the median (range) time since receipt of their most recent previous dose of a COVID-19 ...

Early Estimates of Updated 2023-2024 (Monovalent XBB ... - PubMed

Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection ...

Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 ...

By subvariant period, 3322 (25.8%), 27041 (50.6%) and 15401 (53.9%) controls, respectively, were considered XBB-vaccinated. Overall VE was 30% ( ...

Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs ...

On October 3rd, 2023, the FDA authorized and approved the use of the updated 2023–2024 Novavax COVID-19 vaccine for all individuals ≥12 years of ...

Effectiveness of XBB.1.5 monovalent COVID-19 vaccine against ...

Conclusions Recent booster vaccination with the XBB.1.5 monovalent COVID-19 vaccine is highly effective in preventing COVID-19 mortality ...

Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5 ...

However, few estimates of updated vaccine effectiveness (VE) against medically attended illness are available. ... VE against COVID-19-associated ED/UC encounters ...

Full article: Monovalent XBB.1.5 COVID-19 vaccine effectiveness ...

We aimed to estimate XBB.1.5 vaccine effectiveness (VE) against COVID-19-related hospitalizations and deaths during BA.2.86/JN.1 predominance, among EU/EEA ...

Effectiveness of COVID-19 (2023-2024 Formula) vaccines - FDA

Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness. Against Symptomatic SARS-CoV-2 Infection ...

Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 ...

In this test-negative case-control study, BNT162b2 XBB VE point estimates were 55%–65% against XBB-related outcomes but appeared lower against ...

Effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine in ...

1.5 sublineage. We conducted a multicenter, test-negative, case-control study to estimate XBB.1.5 monovalent vaccine effectiveness (VE) and present the results ...

Comparing the COVID-19 Vaccines: How Are They Different?

In 2022, “bivalent” vaccines targeted both the original virus and Omicron variants BA.4 and BA.5; in 2023, a monovalent shot targeted the XBB ...

Monovalent XBB.1.5 vaccine shows 51% protection against COVID ...

A new interim estimate of vaccine effectiveness (VE) of the monovalent (single-strain) XBB.1.5 COVID-19 vaccine shows the shot was 51% ...

Effectiveness of Omicron XBB.1.5 vaccine against infection with ...

We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and ...

XBB.1.5 updated COVID vaccine booster offers 54% increased ...

The study provided early efficacy estimates of the updated monovalent XBB.1.5 vaccine against symptomatic infection and the first VE ...